title: Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease.
abstract: Amyloid-beta (Aβ) plays a pivotal role in Alzheimer's disease (AD) pathogenesis, and is the most promising disease-modifying target for AD. A succession of failures in Aβ-targeting clinical trials, however, has prompted questions on whether Aβ is the true cause of AD and a valid therapeutic target. Therefore, current therapeutic targets and intervention strategies must be reconsidered. In addition to Aβ, multiple pathological events such as tau hyperphosphorylation, oxidative stress and neuroinflammation are involved in the disease pathogenesis and cause cross-talk between these pathological pathways, which synergistically drive disease progression. Increasing evidence also reveals that the pathogenesis varies at different stages of the disease. Therefore, targeting Aβ alone at all stages of the disease would not be sufficient to halt or reverse disease progression. In the light of the pathophysiologic similarities between the development of ischemic stroke and AD, we can formulate management strategies for AD from the successful practice of ischemic stroke management, namely the tertiary prevention strategy. These new perspectives of tertiary prevention target both Aβ and different pathological pathways of AD pathogenesis at different stages of the disease, and may represent a promising avenue for the effective prevention and treatment of AD.
authors.forename: Xian-Le
authors.initials: XL
authors.lastname: Bu
authors.forename: Shu-Sheng
authors.initials: SS
authors.lastname: Jiao
authors.forename: Yan
authors.initials: Y
authors.lastname: Lian
authors.affiliation: Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China. yanjiang_wang@tmmu.edu.cn.
authors.forename: Yan-Jiang
authors.initials: YJ
authors.lastname: Wang
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism* / Q000628:therapy*; D001921:Brain / Q000378:metabolism; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D018384:Oxidative Stress / Q000502:physiology; D010766:Phosphorylation / Q000502:physiology; D055512:Tertiary Prevention / Q000379:methods* / Q000639:trends; D016875:tau Proteins / Q000378:metabolism
chemical_list: D016875:tau Proteins